false 0001649904 0001649904 2024-09-18 2024-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 18, 2024

 

RHYTHM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38223   46-2159271
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification Number)

 

222 Berkeley Street

12th Floor

Boston, MA 02116

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (857) 264-4280

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)		 Name of each exchange on which registered
Common Stock, $0.001 par value per share RYTM The Nasdaq Stock Market LLC (Nasdaq Global Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On September 18, 2024 Rhythm Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders. At the close of business on the July 24, 2024 record date (the “Record Date”), there were (i) 61,130,640 shares of the Company’s common stock outstanding, of which each share of common stock was entitled to one vote; and (ii) 150,000 shares of the Company’s Series A convertible preferred stock (“Convertible Preferred Stock”) outstanding, of which 90,000 shares were entitled to vote (each share of Convertible Preferred Stock being entitled to a number of votes equal to 20.8333 shares of common stock per $1,000 liquidation preference of Series A convertible preferred stock). As a result, there were a total of 63,005,638 eligible votes as of the record date. A total of 53,945,997 votes were present online or represented by proxy at the meeting, representing approximately 85.6% of the total eligible votes as of the Record Date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s amended and restated definitive proxy statement filed with the Securities and Exchange Commission on August 7, 2024.

 

Item 1 - Election of three Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

 

NOMINEE  Votes FOR  Votes WITHHELD  Broker Non-Votes
Stuart A. Arbuckle  45,585,464  6,530,701  1,829,832
Christophe R. Jean  45,017,705  7,098,460  1,829,832
Lynn A. Tetrault  45,485,067  6,631,098  1,829,832

 

Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024.

 

Votes FOR  Votes AGAINST  Votes ABSTAINED  Broker Non-Votes
53,844,430  69,539  32,028  0

 

Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.

 

Votes FOR  Votes AGAINST  Votes ABSTAINED  Broker Non-Votes
50,612,289  1,487,317  16,559  1,829,832

 

Item 4 - Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.

 

Votes FOR  Votes AGAINST  Votes ABSTAINED  Broker Non-Votes
32,739,796  19,359,379  16,990  1,829,832

 

Based on the foregoing votes, Stuart A. Arbuckle, Christophe R. Jean, and Lynn A. Tetrault were elected as Class I Directors, and Items 2, 3 and 4 were approved. 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RHYTHM PHARMACEUTICALS, INC.
     
Date: September 19, 2024 By: /s/ Hunter Smith
    Hunter Smith
    Chief Financial Officer

 

 

 

v3.24.3
Cover
Sep. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 18, 2024
Entity File Number 001-38223
Entity Registrant Name RHYTHM PHARMACEUTICALS, INC.
Entity Central Index Key 0001649904
Entity Tax Identification Number 46-2159271
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 222 Berkeley Street
Entity Address, Address Line Two 12th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02116
City Area Code 857
Local Phone Number 264-4280
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol RYTM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Rhythm Pharmaceuticals Charts.
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Rhythm Pharmaceuticals Charts.